GD1 was the first lysosomal storage disease to be successfully treated with enzyme therapy, initially in 1991 with placental-derived glucocerebrosidase, (alglucerase, Ceredase®, Genzyme Corporation,1 Cambridge, MA, USA), and beginning in 1994, with recombinant glucocerebrosidase, (imiglucerase, Cerezyme®, Genzyme). Here, GBA1 is linked to lysosomal storage disease.